<DOC>
	<DOCNO>NCT02399007</DOCNO>
	<brief_summary>A clinical trial total Hip system use Primary Total Hip Arthroplasty China .</brief_summary>
	<brief_title>A Clinical Trial Study Hip System Primary Total Hip Arthroplasty China</brief_title>
	<detailed_description>A Prospective , Randomized , Multicenter , Controlled Study Comparing Outcomes Primary Total Hip Arthroplasty Devices Manufactured China versus Devices Manufactured Outside China</detailed_description>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Necrosis</mesh_term>
	<mesh_term>Hip Dislocation</mesh_term>
	<mesh_term>Hip Dislocation , Congenital</mesh_term>
	<criteria>1 . The subject ≥55 , ≤80 year old 2 . The Subject must Chinese ethnic descent willing return three occasion clinical evaluation . 3 . Subject suitable candidate primary total hip replacement use device describe CIP 4 . Subject must meet criterion specify BOTH SUN hip stem Summit hip stem instruction use ( IFU ) 5 . Before surgery , subject willing able sign inform consent form approve Institutional Review Board ( IRB ) , Ethics Committee ( EC ) Ethical Review Board ( ERB ) . 6 . Subject , opinion Clinical Investigator , able understand clinical investigation cooperate investigational procedure . 7 . Subject must comfortable speaking , reading , understand question provide response available translated language patient report outcomes ( PROs ) CIP . 8 . Subject receive unilateral hip replacement , contralateral hip replacement anticipate , surgery must occur within 6 month first study hip . The second hip enrol study . 1 . Subject provide write voluntary consent participate clinical study . 2 . The Subject woman pregnant lactating . 3 . Subjects undergone THA contralateral hip within past 6 month . 4 . Contralateral hip enrol study . 5 . Presence previous prosthetic hip replacement device affect hip . 6 . Previous Girdlestone procedure ( resection arthroplasty ) surgical fusion affect hip 7 . Subject hip dysplasia CROWE classification grade 3 4 . 8 . Above knee amputation either contralateral ipsilateral leg 9 . Subject anticipated require contralateral THA 6 month 1year . 10 . Subject active infection 11 . Subject malignant disease , severe condition , alcohol drug addiction and/or mental disorder investigator believe interfere study participation . 12 . Subjects severe osteoporosis , metabolic bone disease , radioactive bone disease tumor bone surround hip joint , opinion investigator , negatively impact implant fixation outcome investigation ; 13 . Subject significant neurological musculoskeletal disorder disease may adversely affect gait weight bearing ( e.g . muscular dystrophy , multiple sclerosis , cerebral infarction , hemiplegia , Charcot disease ) . 14 . Subject comfortable speaking , reading , understand question provide response available translated language PROs CIP . 15 . Subject medical condition le 2 year life expectancy due medical condition . 16 . The patient comorbid condition ( ) could limit patient 's ability participate study , compliance followup requirement impact scientific integrity study . 17 . The patient currently participate another investigational drug device study . 18 . Subject prisoner . 19 . Subject know allergy component implant ( metal example ) .</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>